Medical/Pharmaceuticals
'The convergence between of AI and the Biology' LG Creates "Next-Generation Protein Structure Prediction AI" for Drug Discovery
SEOUL, South Korea, Feb. 7, 2025 /PRNewswire/ -- On the 5th, LG AI Research signed a joint research agreement at the Global Lounge of LG Science Park in Magok, Gangseo-gu,Seoul, with Prof. Min-Kyung Baek from the school of Biological Sciences at SeoulNational University to develop a "next-generat...
2025-02-07 21:00
5497
GCCL Wins 2025 Asia-Pacific Customer Value Leadership Award by Frost & Sullivan
- GCCL's "One-Stop Lab Solution" sets the industry benchmark with unmatched competitiveness and a dedication to global excellence. - Continuing its growth as a globally recognized leader in clinical sample analysis, driven by customer-centric values. YONGIN, South Korea, Feb. 7, 2025 /...
2025-02-07 09:31
3131
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
HONG KONG, Feb. 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently developed PD-1/VEGF bispecific antibody. Thi...
2025-02-06 09:28
3166
Argent BioPharma: A Hidden Gem traded Under $12M--Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment
PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective trea...
2025-02-06 05:00
3097
Datasea Pre-Announces Second Quarter Revenue of $20.5 Million, up 81% Year-over-Year
Gross Profit achieved a 310% Increase Year-over-Year BEIJING, Feb. 5, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced that its...
2025-02-05 22:30
5343
Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem
Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xaname...
2025-02-05 22:18
4034
I Peace establishes and offers low immunoreaction risk GMP iPS Cells
Three lines of GMP iPS Cells derived from type O female blood are now offered
as off-the-shelf product
PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://ipeace.com/en/
2025-02-05 22:00
3103
From 0 to 100 Trillion: The Rise of Sanyou Bio's Intelligent Molecule Library
SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a deca...
2025-02-05 18:00
2808
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the l...
2025-02-05 13:00
3904
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunol...
2025-02-05 12:28
3274
Sequins™ Announces Availability of First Products - Bolsters Team for Commercialization
SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products – the Sequins Metagenomics Core Control and Whole Genome Sequencing Core Control Sets, along with an ...
2025-02-05 00:00
2679
GC Labs strengthens global ties and explores new opportunities at Medlab Middle East 2025
YONGIN, South Korea, Feb. 4, 2025 /PRNewswire/ -- GC Labs, a leading clinical
laboratory inSouth Korea, announced the successful completion of the second day
of the Medlab Middle East 2025, which is being held at theDubai World Trade
Centre (DWTC), UAE betweenFebruary 3-6.
2025-02-04 14:56
3374
Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has en...
2025-02-03 22:00
4094
HoneyNaps' AI-Powered Sleep Diagnostic Software Designated as 73rd and 74th Innovative Medical Device by South Korea's Ministry of Food and Drug Safety
* Simultaneous approval of AI solutions for diagnosing sleep disorders and digital therapeutics for insomnia * Domestic certification secured following U.S. FDA approval * The only company to possess both AI algorithm development and hardware technology BOSTON, Feb. 3, 2025 /PRNewswire/ -- H...
2025-02-03 22:00
3440
China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth
HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has...
2025-02-03 21:00
6009
Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery
CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), announced today that it has entered into a strategic collaboration with Invetx, Inc. ("Invetx"), aBoston-based animal biotechnology company...
2025-02-03 20:00
2920
Advanced Aesthetic Technologies, Inc. is pleased to announce the approval of Algeness® VL agarose facial injection filler for marketing in China
AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that their partner inChina has obtained approval to market their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose...
2025-01-29 14:00
4539
Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital Chooses a United Imaging Next Generation PET/CT to Revolutionize the Study of Systems Physiology
HOUSTON, Jan. 28, 2025 /PRNewswire/ -- As pioneers in biomedical imaging and neuroscience, the researchers at the Athinoula A. Martinos Center for Biomedical Imaging atMassachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, have long appreciated the ...
2025-01-28 22:00
4085
CStone Partners with SteinCares to Market Sugemalimab in Latin America
* CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. * This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals...
2025-01-27 12:30
3877
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...
2025-01-27 09:53
3578
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
20178
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
18172
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
8438